LLY News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

LL

Mkt Cap

$1.019T

Volume

1.59M

Next Earnings

October 29th

Chart Financials Earnings News About Dividends Insider Filings

Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?Eli Lilly and Novo Nordisk compete in the booming GLP-1 weight-loss and diabetes treatment market. Eli Lilly demonstrates superior growth with 44.7% revenue increase and 49.7% operating margins, while Novo Nordisk offers better valuation (3x lower P/E ratio) and higher dividend yield (4.8% vs 0.6%). The author favors Eli Lilly for growth-oriented investors despite its premium valuation.The Motley Fool · Oct 6, 2026

IYH Beats IXJ on Returns While Global Fund Offers Higher YieldiShares U.S. Healthcare ETF (IYH) outperformed its global counterpart (IXJ) with 28.8% one-year returns versus 22.5%, while IXJ offers higher dividend yield at 1.4%. Both funds have nearly identical expense ratios (0.37-0.38%) and low volatility, with choice depending on whether investors prefer domestic or international healthcare exposure.The Motley Fool · Oct 6, 2026

Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its StockEli Lilly, the only healthcare stock in the trillion-dollar club, has rallied 400% over five years driven by its successful GLP-1 drugs Mounjaro and Zepbound. However, with a valuation of 40x trailing earnings and slowing growth prospects, the stock faces significant headwinds from intensifying competition in the GLP-1 market from companies like Pfizer and Viking Therapeutics. The author suggests the stock may have more downside risk than upside potential at current valuations.The Motley Fool · Oct 5, 2026

Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsightThe type 2 diabetes market is projected to experience steady growth through 2036, driven by rising global prevalence, obesity, and adoption of next-generation therapies including GLP-1 receptor agonists and SGLT2 inhibitors. Key emerging drugs from major pharmaceutical companies like Novo Nordisk, Eli Lilly, and Boehringer Ingelheim are expected to reshape the market landscape with improved glycemic control and weight management benefits.GlobeNewswire Inc. · Oct 5, 2026

FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line SettingEli Lilly announced FDA approval for Jaypirca (pirtobrutinib) as a first-line treatment for previously untreated CLL/SLL patients without 17p deletion. The drug reduced disease progression or death risk by 80% versus chemoimmunotherapy in the phase III BRUIN CLL-313 study. Jaypirca sales grew 66% to $357 million in H1 2026, with the drug's non-covalent BTK inhibitor mechanism differentiating it from competitors like Brukinsa, Calquence, and Imbruvica.Zacks Investment Research · Oct 5, 2026

Here Are My Top 4 Stocks to Buy in OctoberThe article recommends four stocks for October investment: Viking Therapeutics for its unique monthly-dose GLP-1 weight loss drug candidate in a market expected to reach $200 billion by 2030; Alphabet for its dominant position in cloud computing AI services with 82% YoY growth and gaining market share; SoFi Technologies for strong revenue growth (40% YoY) and customer expansion despite recent setbacks; and MercadoLibre for its Amazon-like growth trajectory in Latin America with 50% YoY revenue growth despite margin pressures from free shipping initiatives.The Motley Fool · Oct 5, 2026

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?The VanEck Pharmaceutical ETF (PPH) offers low-cost exposure to the healthcare-pharma sector with a 0.36% expense ratio and $1.01 billion in assets. The fund tracks the MVIS US Listed Pharmaceutical 25 Index and holds major pharmaceutical companies like Eli Lilly, Merck, and Novartis. With a Zacks ETF Rank of 3 (Hold), year-to-date gains of 6.51%, and a medium-risk profile, PPH is presented as a reasonable option for investors seeking diversified pharma exposure, though alternative ETFs like FTXH and IHE are also available.Zacks Investment Research · Oct 5, 2026

Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBBThe article compares two healthcare ETFs: Vanguard Health Care ETF (VHT) offers broad sector exposure with a low 0.09% expense ratio and 1.4% dividend yield, while iShares Biotechnology ETF (IBB) focuses on biotech with higher growth potential (49.8% 1-year return) but greater volatility and a 39.8% maximum drawdown. VHT is recommended for conservative investors seeking stability, while IBB suits high-risk growth investors.The Motley Fool · Oct 5, 2026

Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?Both Pfizer and Novo Nordisk face significant dividend safety concerns despite high yields. Novo Nordisk (4.7% yield) leads in GLP-1 drugs but has lost market share to Eli Lilly and lacks portfolio diversity, while Pfizer (6% yield) faces patent expirations and R&D challenges. However, Pfizer's broader product portfolio and acquisition strategy make it the relatively safer choice for dividend investors, despite both stocks carrying material risk.The Motley Fool · Oct 4, 2026

Wall Street Is Bracing for the Fed's Next Move on Rates. These 3 Stocks Win Either Way.As Wall Street anticipates potential Fed rate hikes, healthcare stocks are positioned to weather economic uncertainty better than other sectors. Three healthcare companies—Eli Lilly, Medtronic, and Johnson & Johnson—are highlighted as resilient investments due to their strong fundamentals, diversified portfolios, and proven ability to generate growth regardless of interest rate environment.The Motley Fool · Oct 3, 2026

LL

LLYEli Lilly & Co.

LLY

Pay with—

Available Balance0.00

Your PositionYou don't own any LLY yet.

Related Tickers

Earnings

Dividends

Last · Aug 14Quarterly

Amount$1.73

Yield0.60%

Annual$6.92